Member access

4-Traders Homepage  >  Shares  >  Nyse  >  ResMed Inc.    RMD   US7611521078

RESMED INC. (RMD)

18
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Analysis summary4-Traders Strategies 

ResMed Inc. : Trading opportunity

02/15/2013 | 05:07am
Opinion : Bullish above USD 42.8
Target price : USD 48.4
Stop loss: USD 40.6
NYSE
Advanced Medical Equipment & Technology
ResMed could regain its upward trend after having run out of steam.

According to Surperformance ratings, the group has strong fundamentals,as shown by the business predictability. In addition, analysts have recently revised upward their earnings estimates and now expect a profit of USD 2.19 per share for the current year.

ResMed is in an uptrend in the medium and long term, but the last bearish movement returns close to a major support level (USD 42.8), level corresponding to the 20-week moving average. This threshold, if preserved, will enable to enjoy the bullish movement towards the USD 48.4 resistance.

It seems opportune to take a long position around the USD 42.8 support area with in line of sight the USD 48.4 resistance. A stop loss must be placed under the USD 42.8 support.

ResMed Inc. : ResMed Inc. : Trading opportunity
Copyright (c) 2014 4-Traders.com



React to this article

Disclaimer: 4-traders.com is a website published by SURPERFORMANCE SAS. Surperformance or 4-traders.com is not a registered broker-dealer nor a registered investment adviser. You understand that this web site and its content is furnished for your personal, noncommercial, informational purposes only, and that no mention of a particular security in this website constitutes a recommendation to buy, sell, or hold any other security, nor that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person. Surperformance and 4-traders.com services will not advise you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. Information regarding trading and investment as provided by Surperformance professional is not tailored to the investment needs of any specific person. You acknowledge that you are responsible for your own financial decisions and should seek a registered financial agent depending on your own risk tolerance to advise you on your personal trading activities.

Advertisement
Financial Ratios

Size 2015e 2016e
Capitalization 7 230 M$ -
Entreprise Value (EV) 6 569 M$ 6 448 M$
Valuation 2015e 2016e
PER (Price / EPS) 20,2x 18,2x
Capitalization / Revenue 4,34x 4,01x
EV / Revenue 3,94x 3,58x
EV / EBITDA 12,8x 11,5x
Yield (DPS / Price) 2,16% 2,41%
Profitability 2015e 2016e
Operating Margin (EBIT / Sales) 25,9% 26,7%
operating Leverage (Delta EBIT / Delta Sales) 0,46x 1,40x
Net Margin (Net Profit / Revenue) 21,5% 21,6%
ROA (Net Profit / Asset) 19,2% 20,3%
ROE (Net Profit / Equities) 20,5% 21,4%
Rate of Dividend 43,7% 44,0%
Balance Sheet Analysis 2015e 2016e
CAPEX / Sales   4,78% 4,88%
Cash Flow / Sales (Taux d'autofinancement) 26,6% 26,2%
Capital Intensity (Assets / Sales) 1,12x 1,06x
Financial Leverage (Net Debt / EBITDA) -1,29x -1,40x
Income Statement Evolution
ResMed Inc. : Income Statement Evolution
More Financials
EPS Revisions
ResMed Inc. : EPS Revisions
Dynamic quotes  
ON
| OFF